Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2010 | 1 |
2016 | 1 |
2017 | 1 |
2018 | 1 |
2019 | 1 |
2020 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
Clin Breast Cancer. 2022 Apr;22(3):269-278. doi: 10.1016/j.clbc.2021.10.011. Epub 2021 Oct 28.
Clin Breast Cancer. 2022.
PMID: 34824002
Clinical Trial.
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.
Wu TC, Xu K, Martinek J, Young RR, Banchereau R, George J, Turner J, Kim KI, Zurawski S, Wang X, Blankenship D, Brookes HM, Marches F, Obermoser G, Lavecchio E, Levin MK, Bae S, Chung CH, Smith JL, Cepika AM, Oxley KL, Snipes GJ, Banchereau J, Pascual V, O'Shaughnessy J, Palucka AK.
Wu TC, et al. Among authors: young rr.
Cancer Res. 2018 Sep 15;78(18):5243-5258. doi: 10.1158/0008-5472.CAN-18-0413. Epub 2018 Jul 16.
Cancer Res. 2018.
PMID: 30012670
Free PMC article.
Clinical Trial.
Item in Clipboard
A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA, Liggett W, Mainwaring M, Castrellon A, Blakely L, Hemphill B, Anz B 3rd, Young RR, Shastry M, DeBusk LM, Hainsworth JD, Burris HA 3rd.
Yardley DA, et al. Among authors: young rr.
Clin Breast Cancer. 2020 Apr;20(2):89-97. doi: 10.1016/j.clbc.2019.06.005. Epub 2019 Jun 26.
Clin Breast Cancer. 2020.
PMID: 31932237
Clinical Trial.
Item in Clipboard
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Yardley DA, Arrowsmith ER, Daniel BR, Eakle J, Brufsky A, Drosick DR, Kudrik F, Bosserman LD, Keaton MR, Goble SA, Bubis JA, Priego VM, Pendergrass K, Manalo Y, Bury M, Gravenor DS, Rodriguez GI, Inhorn RC, Young RR, Harwin WN, Silver C, Hainsworth JD, Burris HA 3rd.
Yardley DA, et al. Among authors: young rr.
Breast Cancer Res Treat. 2017 Aug;164(3):649-658. doi: 10.1007/s10549-017-4285-6. Epub 2017 May 15.
Breast Cancer Res Treat. 2017.
PMID: 28508185
Clinical Trial.
Item in Clipboard
Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy.
Hainsworth JD, Murphy PB, Alemar JR, Daniel BR, Young RR, Yardley DA.
Hainsworth JD, et al. Among authors: young rr.
Breast Cancer Res Treat. 2016 Nov;160(1):41-49. doi: 10.1007/s10549-016-3969-7. Epub 2016 Sep 8.
Breast Cancer Res Treat. 2016.
PMID: 27632289
Item in Clipboard
A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
Hortobagyi GN, Young RR, Karwal M, Ibrahim NK, Hermann R, Murray JL, Watkins SP, Gore I Jr.
Hortobagyi GN, et al. Among authors: young rr.
Cancer. 2010 May 15;116(10):2301-6. doi: 10.1002/cncr.25042.
Cancer. 2010.
PMID: 20225231
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite